Pharmaceuticals

Autoimmune Monoclonal Antibody Market Trends 2025–2029: Forecasts for Key Growth Segments

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Autoimmune Monoclonal Antibody Industry Compare Between 2025 And 2029?

The autoimmune monoclonal antibody market size has experienced significant expansion over recent years. It is projected to expand from $65.83 billion in 2024 to $70.86 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 7.6%. Historically, this growth has been driven by factors such as the rising incidence of autoimmune diseases, the increasing adoption of biologics for treatment, heightened awareness regarding targeted therapies, prompt approvals for monoclonal antibody drugs, and broadened healthcare access in developed nations.

The autoimmune monoclonal antibody market is projected to experience substantial growth in the coming years, reaching $96.74 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%. This expansion is primarily driven by factors such as the increasing demand for personalized medicine, a rising adoption of biosimilars, the expansion of clinical trials in autoimmune therapy, a growing geriatric population, and the escalating prevalence of chronic immune disorders. Key trends anticipated during this forecast period include advancements in antibody engineering, the development of bispecific antibodies, an increasing application of artificial intelligence in drug discovery, the integration of genomics in treatment planning, and the emergence of novel drug delivery systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp

Which Factors And Drivers Are Influencing The Autoimmune Monoclonal Antibody Market In 2025?

The rising need for biologics is projected to boost the expansion of the autoimmune monoclonal antibody market in the future. Biologics are a class of medicinal products originating from living organisms or their parts, utilized for treating, preventing, or diagnosing illnesses. The growing requirement for biologics largely stems from their efficacy in addressing intricate diseases like cancer, autoimmune conditions, and genetic ailments, particularly when conventional treatments prove less potent. Autoimmune monoclonal antibody improves biologic treatments through precise immune modulation, rendering them effective in controlling excessive immune reactions. These antibodies lessen the reliance on general immunosuppressants by delivering targeted treatment, thereby enhancing patient results and lessening adverse effects. As an illustration, in June 2024, data from Cardinal Health Inc., a US-based healthcare company, indicated that 40 Food and Drug Administration (FDA) approved biosimilar products existed in 2023, with 25 of these available commercially in the US market, marking a rise from 33 biosimilar products in 2022. Consequently, the expanding demand for biologics is fueling the growth of the autoimmune monoclonal antibody market.

What Are The Key Segments In The Autoimmune Monoclonal Antibody Market?

The autoimmune monoclonal antibody market covered in this report is segmented –

1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular

3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions

Subsegments:

1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)

2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)

3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region

4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived

What Trends Are Expected To Drive The Autoimmune Monoclonal Antibody Market?

Leading companies in the autoimmune monoclonal antibody sector are concentrating on developing innovative solutions, such as biosimilar development, to boost safety, effectiveness, and overall quality. Biosimilar development entails creating biological products that are highly similar, safe, and potent to existing approved biologics, employing advanced biotechnology, thorough analytical testing, and clinical studies to demonstrate comparable quality, efficacy, and safety for regulatory clearance. For example, in February 2025, Biocon Biologics Limited, an India-based biopharmaceutical company, introduced YESINTEK, a biosimilar designed to treat autoimmune conditions like Crohn’s disease, ulcerative colitis, and psoriasis. It achieves this by targeting and inhibiting the activity of interleukin-12 and interleukin-23, thereby reducing inflammation and modulating the immune response. Yesintek, by mimicking the reference product Stelara, contributes to long-term disease management while enhancing patient access to biologic therapies.

Which Industry Leaders Are Driving Innovation Across The Autoimmune Monoclonal Antibody Market?

Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/autoimmune-monoclonal-antibody-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Autoimmune Monoclonal Antibody Market?

North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Autoimmune Monoclonal Antibody Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp

Browse Through More Reports Similar to the Global Autoimmune Monoclonal Antibody Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Autoimmune Disease Diagnosis Market 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795